In fact, prior to the recent publication of direct evidence that CD8 can function in cancer via ferroptosis (20), numerous previous works unveiled that ferroptosis enhances anti-cancer immunity by boosting cancer immunosurveillance and deciding the fate of CD8+ T cells via glutathione oxidase 4 (GPX4), which is a key enzyme in the removing lipid reactive oxygen species (ROS) and ferroptosis (31, 32). The gene discussed is GPX4; the disease is cancer.